The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
Open accessAbstract
Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferator-activated receptor (PPAR)α deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPARα would promote tumor growth. Surprisingly, the PPARα agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPARα-deficient tumors were still susceptible to fenofibrate, absence of PPARα in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPARα as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tolerated PPARα agonists beyond their use as lipid-lowering drugs in anticancer therapy. Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARα agonists in cancer treatment, alone and in combination with other therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Self-citationThe mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Self-citationThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 5×
“Bezafibrate is a pan-PPAR agonist that activates all three nuclear receptors, PPAR , PPAR , and PPAR (22).”
BackgroundInfluentialThe anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Sorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Band Horwitz, S. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90048-b · Cited by 740
Moulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, W., & Folkman, J. (1999) · Circulation · doi:10.1161/01.cir.99.13.1726 · Cited by 688
Self-citationMarx, N., Sukhova, G. K., Collins, T., Libby, P., & Plutzky, J. (1999) · Circulation · doi:10.1161/01.cir.99.24.3125 · Cited by 599
Peroxisome-proliferator-activated receptors and cancers: complex stories
Michalik, L., Desvergne, B., & Wahli, W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1254 · Cited by 573
Peters, J. (1997) · Carcinogenesis · doi:10.1093/carcin/18.11.2029 · Cited by 479
Endostatin's Antiangiogenic Signaling Network
Abdollahi, A., Hahnfeldt, P., Maercker, C., Gröne, H.-J., Debus, J., Ansorge, W., Folkman, J., Hlatky, L., & Huber, P. E. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00102-9 · Cited by 393
Self-citationPeroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215634 · Cited by 276
Self-citationTanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., & Hosokawa, M. (2001) · PubMed · Cited by 270
Activation of PPARβ/δ Induces Endothelial Cell Proliferation and Angiogenesis
Piqueras, L., Reynolds, A. R., Hodivala-Dilke, K. M., Alfranca, A., Redondo, J. M., Hatae, T., Tanabe, T., Warner, T. D., & Bishop-Bailey, D. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000250972.83623.61 · Cited by 246
PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C., Zhang, F., Leone, T. C., Coleman, T., Kelly, D. P., & Semenkovich, C. F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11497 · Cited by 229
Kieran, M. W., Turner, C. D., Rubin, J. B., Chi, S. N., Zimmerman, M. A., Chordas, C., Klement, G., Laforme, A., Gordon, A., Thomas, A., et al. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000183863.10792.d4 · Cited by 199
Self-citationDuez, H., Chao, Y.-S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C. A., Tedgui, A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206966200 · Cited by 186
Optimizing bexarotene therapy for cutaneous T-cell lymphoma
Talpur, R., Ward, S., Apisarnthanarax, N., Breuer-McHam, J., & Duvic, M. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.124607 · Cited by 185
Niho, N., Takahashi, M., Kitamura, T., Shoji, Y., Itoh, M., Noda, T., Sügimura, T., & Wakabayashi, K. (2003) · PubMed · Cited by 164
PPAR activators inhibit endothelial cell migration by targeting Akt
Goetze, S., Eilers, F., Bungenstock, A., Kintscher, U., Stawowy, P., Blaschke, F., Graf, K., Law, R. E., Fleck, E., & Gräfe, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00385-6 · Cited by 154
Grabacka, M., Plonka, P. M., Urbańska, K., & Reiss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2556 · Cited by 154
Suchanek, K. M., May, F. J., Robinson, J. A., Lee, W. J., Holman, N. A., Monteith, G. R., & Roberts‐Thomson, S. J. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10061 · Cited by 140
Maggiora, M., Bologna, M., Cerù, M. P., Possati, L., Angelucci, A., Cimini, A., Miglietta, A., Bozzo, F., Margiotta, C., Muzio, G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20519 · Cited by 131
Pozzi, A., Ibáñez, M. R., Gatica, A., Yang, S., Wei, S. D., Mei, S., Falck, J. R., & Capdevila, J. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701429200 · Cited by 115
Blann, A. D., Belgore, F. M., Constans, J., Conri, C., & Lip, G. Y. H. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01486-2 · Cited by 113
Meißner, M., Stein, M., Urbich, C., Reisinger, K., Suske, G., Staels, B., Kaufmann, R., & Gille, J. (2003) · Circulation Research · doi:10.1161/01.res.0000113781.08139.81 · Cited by 110
PPARα Deficiency in Inflammatory Cells Suppresses Tumor Growth
Kaipainen, A., Kieran, M. W., Huang, S., Butterfield, C., Bielenberg, D. R., Mostoslavsky, G., Mulligan, R. C., Folkman, J., & Panigrahy, D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000260 · Cited by 98
Self-citationFenofibrate inhibits angiogenesis in vitro and in vivo
Pille, J., Varet, J., Vincent, L., Mirshahi, P., Legrand, E., Opolon, P., Mishal, Z., Soria, J., Li, H., & Soria, C. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2322-6 · Cited by 97
Grau, R., Punzón, C., Fresno, M., & Iñiguez, M. A. (2006) · Biochemical Journal · doi:10.1042/bj20050964 · Cited by 94
Saidi, S. A., Holland, C. M., Jones, D. S., & Smith, S. K. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-13 · Cited by 92
Yokoyama, Y., Xin, B., Shigeto, T., Umemoto, M., Kasai-Sakamoto, A., Futagami, M., Tsuchida, S., Al‐Mulla, F., & Mizunuma, H. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0722 · Cited by 91
Inhibition of melanoma metastases by fenofibrate
Grabacka, M., Placha, W., Plonka, P. M., Pajak, S., Urbańska, K., Laidler, P. M., & Slominski, A. T. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0479-y · Cited by 79
Melanoma Chemoprevention: A Role for Statins or Fibrates?
Dellavalle, R. P., Nicholas, M. K., & Schilling, L. M. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200305000-00007 · Cited by 38
Kasai, T., Miyauchi, K., Yokoyama, T., Aihara, K., & Daida, H. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.047 · Cited by 25
Cited by
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao, Y., Shen, M., Wu, L., Yang, H., Yao, Y., Yang, Q., Du, J., Liu, L., Li, Y., & Bai, Y. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06110-6 · Cited by 431
Regulation of Angiogenesis by Oxygen and Metabolism
Fraisl, P., Mazzone, M., Schmidt, T., & Carmeliet, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.003 · Cited by 413
Metadata
- Authors
- Panigrahy, D., Kaipainen, A., Huang, S., Butterfield, C. E., Barnés, C. M., Fannon, M., Laforme, A. M., Chaponis, D. M., Folkman, J., & Kieran, M. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-01-22
- Volume
- 105
- Issue
- 3
- Pages
- 985-990
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2088386132
- Cited by
- 269
- References
- 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.